Eli Lilly (LLY) Long-Term Debt Issuances (2009 - 2025)

Eli Lilly has reported Long-Term Debt Issuances for 12 years, with the latest figure at -$200000.0 in Q4 2025.

• For the quarter ending Q4 2025, Long-Term Debt Issuances fell 100.0% year-over-year to -$200000.0; the trailing twelve-month figure through Mar 2026 stood at $6.7 billion (down 41.31% YoY), and the FY2025 full-year result was $13.2 billion, up 15.33% from the prior year.
• Long-Term Debt Issuances for Q4 2025 stood at -$200000.0, down from $6.7 billion in the prior quarter.
• The five-year high for Long-Term Debt Issuances was $6.7 billion in Q3 2025, with the low at -$200000.0 in Q4 2025.
• Historically, Long-Term Debt Issuances has averaged $3.4 billion across 4 years, with a median of $4.0 billion in 2023.
• Annual changes were most pronounced in 2021 — Long-Term Debt Issuances surged 124.53% — and 2024, when it slumped 120.0%.
• Eli Lilly's Long-Term Debt Issuances stood at $2.4 billion in 2021, then tumbled by 99.98% to $500000.0 in 2023, then slumped by 120.0% to -$100000.0 in 2024, then sank by 100.0% to -$200000.0 in 2025.
• The last three Long-Term Debt Issuances figures came in at -$200000.0 (Q4 2025), $6.7 billion (Q3 2025), and $6.5 billion (Q1 2025), per Business Quant data.